ALSO NOTED: Omrix inks R&D pact; Advaxis program gets a close-up; and much more...

> Omrix Biopharmaceuticals says it has signed an R&D pact with the NIAID to develop a new avian flu therapy. No terms were disclosed. Report

> The New Jersey Star-Ledger examines the prospects of Advaxis, which has been using genetically engineered bacterium to provoke T-cells to attack cancerous tumors. Other researchers have been focused on different proteins to go after tumors. Report

> Citing a lack of funding, the board of Fairfield, NJ-based Astralis says that they're considering various alternatives, including the sale of the company. Release

> Chutes & Ladders: Johnson & Johnson CFO Robert J. Darretta is retiring after 38 years at the company. Report

> Bristol-Myers Squibb says it has added a new warning on its blood-thinner drug Coumadin. Report

> Four defendants will stand trial on charges that their online pharmacy--Xpress Pharmacy Direct--was little more than a conduit for prescription drug addicts to obtain controlled substances. Report

And Finally... Analysts say that the long and painful beating that pharma stocks have been taking may be over. Some analysts say the share prices have begun to look low, and that possibly the worst is over in the big pharma sector. Article

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.